Guizhi Fuling Wan as a Novel Agent for Intravesical Treatment for Bladder Cancer in a Mouse Model.

Alternative intravesical agents are required to overcome the side effects currently associated with the treatment of bladder cancer. This study used an orthotopic bladder cancer mouse model to evaluate Guizhi Fuling Wan (GFW) as an intravesical agent. The effects of GFW were compared with those of mitomycin-C (Mito-C) and bacille Calmette-Guérin (BCG).

The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder.

Background: The high risk of recurrence faced by patients with bladder cancer has necessitated the administration of supplemental intravesical chemotherapy; however, such treatments often result in severe side effects. As a result, novel intravesical agents with enhanced efficacy and minimal toxicity are urgently required for the treatment of bladder cancer.

Methods: Guizhi Fuling Wan (GFW) is a traditional Chinese medicine shown to inhibit the growth of hepatocellular carcinoma.

Electroacupuncture induces differential effects between Yin and Yang: a study using cutaneous blood flow and temperature recordings of the hand's dorsum and palm.

The underlying theory of traditional Chinese Medicine (TCM) considers that Yin and Yang are in the opposition with each other and play different roles in physiological responses. Several studies have reported that electroacupuncture (EA) produces a greater effect than manual acupuncture (MA), and that the effect of EA is similar to transcutaneous electric nerve stimulation (TENS). Therefore, the purpose of the present study was to investigate the differences between Yin and Yang induced by acupuncture.